BPTH

Bio Path (BPTH)

Bio Path Holdings Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:BPTH

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/08	20:00	GlobeNewswire Inc.	Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024	NASDAQ:BPTH	Bio Path Holdings Inc
2024/04/20	01:14	GlobeNewswire Inc.	Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	NASDAQ:BPTH	Bio Path Holdings Inc
2024/04/19	02:57	GlobeNewswire Inc.	Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	NASDAQ:BPTH	Bio Path Holdings Inc
2024/04/18	20:00	GlobeNewswire Inc.	Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients	NASDAQ:BPTH	Bio Path Holdings Inc
2024/04/15	20:00	GlobeNewswire Inc.	Bio-Path Holdings Expands Global Patent Portfolio	NASDAQ:BPTH	Bio Path Holdings Inc
2024/04/02	20:00	GlobeNewswire Inc.	Bio-Path Holdings Provides 2024 Clinical and Operational Update	NASDAQ:BPTH	Bio Path Holdings Inc
2024/03/11	20:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BPTH	Bio Path Holdings Inc
2024/03/09	07:11	Edgar (US Regulatory)	Form S-1 - General form for registration of securities under the Securities Act of 1933	NASDAQ:BPTH	Bio Path Holdings Inc
2024/03/08	21:10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BPTH	Bio Path Holdings Inc
2024/03/08	21:00	GlobeNewswire Inc.	Bio-Path Holdings Reports Full Year 2023 Financial Results	NASDAQ:BPTH	Bio Path Holdings Inc
2024/03/08	20:22	IH Market News	U.S. Index Futures Fluctuate Ahead of Key Jobs Report; Oil Prices Dip	NASDAQ:BPTH	Bio Path Holdings Inc
2024/03/08	06:21	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:BPTH	Bio Path Holdings Inc
2024/03/01	21:00	GlobeNewswire Inc.	Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024	NASDAQ:BPTH	Bio Path Holdings Inc
2024/02/29	20:00	Edgar (US Regulatory)	Form RW - Registration Withdrawal Request	NASDAQ:BPTH	Bio Path Holdings Inc
2024/02/23	21:01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BPTH	Bio Path Holdings Inc
2024/02/21	21:00	GlobeNewswire Inc.	Bio-Path Holdings Announces 1-for-20 Reverse Stock Split	NASDAQ:BPTH	Bio Path Holdings Inc
2024/02/03	06:39	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:BPTH	Bio Path Holdings Inc
2024/02/03	06:10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BPTH	Bio Path Holdings Inc
2024/01/24	07:20	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BPTH	Bio Path Holdings Inc
2024/01/24	06:51	Edgar (US Regulatory)	Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]	NASDAQ:BPTH	Bio Path Holdings Inc
2024/01/18	06:52	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:BPTH	Bio Path Holdings Inc
2024/01/11	06:10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BPTH	Bio Path Holdings Inc
2024/01/10	21:00	GlobeNewswire Inc.	Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients	NASDAQ:BPTH	Bio Path Holdings Inc
2024/01/05	07:18	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:BPTH	Bio Path Holdings Inc
2023/12/23	06:06	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:BPTH	Bio Path Holdings Inc
2023/12/23	06:05	Edgar (US Regulatory)	Form S-1 - General form for registration of securities under the Securities Act of 1933	NASDAQ:BPTH	Bio Path Holdings Inc
2023/12/16	06:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BPTH	Bio Path Holdings Inc
2023/12/15	06:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BPTH	Bio Path Holdings Inc
2023/12/14	21:00	GlobeNewswire Inc.	Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia	NASDAQ:BPTH	Bio Path Holdings Inc
2023/12/09	06:05	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:BPTH	Bio Path Holdings Inc